<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568772</url>
  </required_header>
  <id_info>
    <org_study_id>Tegoprazan_CYP2C19_DDI</org_study_id>
    <nct_id>NCT04568772</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Three-period Crossover Clinical Trial to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the influence of tegoprazan on the pharmacokinetics of&#xD;
      proguanil in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation criteria&#xD;
&#xD;
        -  Pharmacokinetic assessment with plasma concentrations of proguanil and cycloguanil&#xD;
&#xD;
        -  Safety assessments with adverse event monitoring including subjective/objective&#xD;
           symptoms, physical examination, vital signs, electrocardiogram, and laboratory tests&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Actual">August 3, 2021</completion_date>
  <primary_completion_date type="Actual">July 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of proguanil, cycloguanil</measure>
    <time_frame>Pre-dose(0 hour) and up to 48 hours in each period</time_frame>
    <description>Systemic exposure of proguanil and cycloguanil</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of proguanil</measure>
    <time_frame>Pre-dose(0 hour) and up to 48 hours in each period</time_frame>
    <description>Secondary pharmacokinetic parameters of proguanil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of proguanil</measure>
    <time_frame>Pre-dose(0 hour) and up to 48 hours in each period</time_frame>
    <description>Secondary pharmacokinetic parameters of proguanil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of proguanil</measure>
    <time_frame>Pre-dose(0 hour) and up to 48 hours in each period</time_frame>
    <description>Secondary pharmacokinetic parameters of proguanil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of proguanil</measure>
    <time_frame>Pre-dose(0 hour) and up to 48 hours in each period</time_frame>
    <description>Secondary pharmacokinetic parameters of proguanil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of proguanil</measure>
    <time_frame>Pre-dose(0 hour) and up to 48 hours in each period</time_frame>
    <description>Secondary pharmacokinetic parameters of proguanil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F of proguanil</measure>
    <time_frame>Pre-dose(0 hour) and up to 48 hours in each period</time_frame>
    <description>Secondary pharmacokinetic parameters of proguanil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe of proguanil</measure>
    <time_frame>Pre-dose(0 hour) and up to 48 hours in each period</time_frame>
    <description>Secondary pharmacokinetic parameters of proguanil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR of proguanil</measure>
    <time_frame>Pre-dose(0 hour) and up to 48 hours in each period</time_frame>
    <description>Secondary pharmacokinetic parameters of proguanil</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Atovaquone/Proguanil 250/100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single oral administration of atovaquone/proguanil 250/100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tegoprazan 50 mg + Atovaquone/Proguanil 250/100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of tegoprazan 50 mg once daily for 6 days and then co-administration of tegoprazan 50 mg and atovaquone/proguanil 250/100 mg at 7 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 40 mg + Atovaquone/Proguanil 250/100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of esomeprazole 40 mg once daily for 6 days and then co-administration of esomeprazole 40 mg and atovaquone/proguanil 250/100 mg at 7 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vonoprazan 20 mg + Atovaquone/Proguanil 250/100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of vonoprazan 20 mg once daily for 6 days and then co-administration of vonoprazan 20 mg and atovaquone/proguanil 250/100 mg at 7 day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone / Proguanil 250/100 mg</intervention_name>
    <description>Atovaquone / Proguanil 250/100 mg tablet</description>
    <arm_group_label>Atovaquone/Proguanil 250/100 mg</arm_group_label>
    <arm_group_label>Esomeprazole 40 mg + Atovaquone/Proguanil 250/100 mg</arm_group_label>
    <arm_group_label>Tegoprazan 50 mg + Atovaquone/Proguanil 250/100 mg</arm_group_label>
    <arm_group_label>Vonoprazan 20 mg + Atovaquone/Proguanil 250/100 mg</arm_group_label>
    <other_name>Malarone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan 50 mg</intervention_name>
    <description>Tegoprazan 50 mg tablet</description>
    <arm_group_label>Tegoprazan 50 mg + Atovaquone/Proguanil 250/100 mg</arm_group_label>
    <other_name>K-cab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40 mg</intervention_name>
    <description>Esomeprazole 40 mg tablet</description>
    <arm_group_label>Esomeprazole 40 mg + Atovaquone/Proguanil 250/100 mg</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan 20 mg</intervention_name>
    <description>Vonoprazan 20 mg tablet</description>
    <arm_group_label>Vonoprazan 20 mg + Atovaquone/Proguanil 250/100 mg</arm_group_label>
    <other_name>Takecab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult aged ≥ 19 years and ≤ 50 years at the time of screening&#xD;
&#xD;
          -  Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 19.0 kg/m2 and&#xD;
             ≤ 30.0 kg/m2 at the time of screening&#xD;
&#xD;
          -  Extensive metabolizer (*1/*1) by CYP2C19 genotyping&#xD;
&#xD;
          -  A subject without any congenital or chronic disease, and has no medical examination&#xD;
             result as pathological symptoms or signs&#xD;
&#xD;
          -  A subject who listened to sufficient explanation and fully understood this study, and&#xD;
             voluntarily decided to participate and agreed in writing to comply with the&#xD;
             precautions&#xD;
&#xD;
          -  A subject determined eligible for this study by investigator based physical&#xD;
             examination, clinical laboratory tests, interview, etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject with clinically significant hepatobiliary (severe hepatic impairment, etc.),&#xD;
             renal (severe renal impairment, etc.), neurologic, immunologic, respiratory,&#xD;
             gastrointestinal, endocrine, blood•oncology, cardiovascular (heart failure, Torsades&#xD;
             de pointes, etc.), urinary, or, psychical diseases (except for simple dental past&#xD;
             history such as tartar, impacted tooth, or wisdom tooth) or a history&#xD;
&#xD;
          -  A subject who has hypersensitivity to the investigational products, drugs containing&#xD;
             the same class, or other drugs (penicillin and antibiotics, etc.), or a history of&#xD;
             clinically significant hypersensitivity&#xD;
&#xD;
          -  A subject with a history of gastrointestinal disorders (gastrointestinal ulcer,&#xD;
             gastritis, gastrospasm, gastroesophageal reflux disease, Crohn's disease, etc.) or&#xD;
             surgery (except for simple appendectomy and herniotomy) that may affect the safety and&#xD;
             pharmacokinetics of the investigational products&#xD;
&#xD;
          -  A subject with the following results in the screening test:&#xD;
&#xD;
          -  Blood AST (GOT), ALT (GPT): &gt; Normal range upper × 1.5&#xD;
&#xD;
          -  Creatinine clearance calculated by MDRD equation: &lt; 80mL/min&#xD;
&#xD;
          -  QTc interval: &gt; 450 ms&#xD;
&#xD;
          -  Fasting serum glucose: &gt; 126 mg/dL&#xD;
&#xD;
          -  Positive serological test (syphilis test, hepatitis B test, hepatitis C test, human&#xD;
             immunodeficiency virus (HIV) test)&#xD;
&#xD;
          -  A subject with systolic blood pressure &lt; 90 mmHg or &gt; 150 mmHg, or diastolic blood&#xD;
             pressure &lt; 50 mmHg or &gt; 100 mmHg when vital signs are measured in sitting position&#xD;
             after resting for at least 3 minutes&#xD;
&#xD;
          -  A subject with a history of or positive urine screening for drug abuse&#xD;
&#xD;
          -  A subject who administered any prescription drugs or herbal medicine within 2 weeks&#xD;
             prior to the expected date of the first dose, or any over-the-counter drug (OTC drug,&#xD;
             health functional food or vitamin within 1 week prior to the expected date of the&#xD;
             first dose (However, can participate in the study if otherwise decided eligible by the&#xD;
             investigator), or is expected to administer it&#xD;
&#xD;
          -  A subject who administered drugs that induce or inhibit the drug metabolizing enzymes,&#xD;
             such as barbitals, within 1 week prior to the expected date of the first dose&#xD;
&#xD;
          -  A subject who participated in other clinical trial or bioequivalence study within 6&#xD;
             months prior to the expected date of the first dose&#xD;
&#xD;
          -  A subject who donated whole blood within 2 months or the component blood within 1&#xD;
             month prior to the expected date of the first dose, or received blood transfusion&#xD;
             within 1 month prior to the expected date of the first dose&#xD;
&#xD;
          -  A subject with persistent alcohol intake (&gt; 21 units/week, 1 unit = 10 g of pure&#xD;
             alcohol), or inability to abstain from drinking from 3 days before the expected date&#xD;
             of the first dose until the last discharge&#xD;
&#xD;
          -  A subject who is a currently smoker (But, can be eligible if he or she quitted smoking&#xD;
             3 months ago), or is not able to cease smoking from 3 months before the expected date&#xD;
             of the first dose until the last discharge&#xD;
&#xD;
          -  A subject with inability to refrain from grapefruit-containing food from 3 days before&#xD;
             the expected date of the first dose until the last discharge&#xD;
&#xD;
          -  A subject with excessive caffeine intake (&gt; 5 units/day), or inability to refrain from&#xD;
             caffeine or caffeine-containing food from 3 days before the expected date of the first&#xD;
             dose until the last discharge&#xD;
&#xD;
          -  A subject with inability to use a medically acceptable double contraception or&#xD;
             contraception throughout the study and for at least 4 weeks after the last dose, and&#xD;
             with inability to agree to donate sperm until the period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SeungHwan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital, Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>SeungHwan Lee</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atovaquone</mesh_term>
    <mesh_term>Proguanil</mesh_term>
    <mesh_term>Atovaquone, proguanil drug combination</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

